Tevogen Bio (NASDAQ:TVGN) Shares Up 4.5%

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares traded up 4.5% during trading on Friday . The stock traded as high as $0.46 and last traded at $0.46. 372,213 shares traded hands during trading, a decline of 24% from the average session volume of 488,400 shares. The stock had previously closed at $0.44.

Analyst Upgrades and Downgrades

Separately, Fundamental Research set a $4.20 price objective on Tevogen Bio and gave the stock a “buy” rating in a research report on Friday, June 28th.

Tevogen Bio Stock Up 4.5 %

The stock has a fifty day moving average of $0.58 and a 200-day moving average of $1.55.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tevogen Bio stock. Portland Global Advisors LLC purchased a new stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio comprises approximately 3.0% of Portland Global Advisors LLC’s portfolio, making the stock its 9th largest holding. Portland Global Advisors LLC owned about 36.55% of Tevogen Bio as of its most recent SEC filing.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.